Low daily dose of antioxidant probucol decreases incidence and severity of restenosis after transluminal coronary balloon angioplasty

Bulletin of Experimental Biology and Medicine

Volumn 139, Issue 2, 2005, Pages 183-185

  Kaminnyi, A I ^a   Lankin, V Z ^a   Samko, A N ^a   Sozykin, A L ^a   Provatorov, S I ^a   Konovalova, G G ^a   Perepelitsa, E I ^a   Tikhaze, A K ^a   Polevaya, T Yu ^a   Kukharchuk, V V ^a   Belenkov, Yu N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Antioxidants; Inflammation; Restenosis; Thrombosis; Transluminal balloon coronary angioplasty

Indexed keywords

ALCOLEX; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; PROBUCOL;

ADULT; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INCIDENCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; QUANTITATIVE ANALYSIS; RESTENOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIOXIDANTS; CORONARY RESTENOSIS; CORONARY STENOSIS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROBUCOL;

EID: 25144452012     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-005-0242-1     Document Type: Article

References (15)

1. Yu. N. Belenkov, T. A. Batyraliev, I. V. Pershukov, and A. N. Samko, Kardiologiya, 11, No.9, 68-72 (2002).
2. N. K. Zenkov, N. V. Kandalintseva, V. Z. Lankin, et al., Phenol Bioantioxidants [in Russian], Novosibirsk (2003).
3. N. K. Zenkov, V. Z. Lankin, and E. B. Men'shchikova, Oxidative Stress: Biochemical and Pathophysiological Aspects [in Russian], Moscow (2001).
4. V. Z. Lankin, A. K. Tikhaze, and Yu. N. Belenkov, Kardiologiya, 40, No.7, 48-61 (2000).
5. A. K. Tikhaze, V. Z. Lankin, G. G. Konovalova, et al., Byull. Eksp. Biol. Med., 128, No.8, 186-189 (1999).
6. B. G. Brown, E. Bolson, M. Frimer, et al. Circulation, 55, 329-337 (1977). 1:STN:280:CSiD1cbnsFE%3D
7. D. L. Fischman, M. B. Leon, D. S. Baim, et al., N. Engl. J. Med., 331, 496-501 (1994). 1:STN:280:ByuA3MnisFQ%3D
8. G. Hansson, C. Malmsten, and O. Radmark, in: Prostaglandins and Related Substances, Amsterdam, New York, Oxford (1983), pp. 127-169.
9. C. Landau, R. A. Lange, and L. D. Hillis, N. Engl. J. Med., 330, 981-993 (2003).
10. A. C. Newby, Toxicol. Lett., 112-113, 519-529 (2000). 10720775
11. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, and S. P. Wolff, Anal. Biochem., 220, 403-409 (1994). 1:CAS:528:DyaK2cXlt12itLw%3D
12. J. Rodest, G. Cote, J. Lesperanse, et al., N. Engl. J. Med., 337, 365-372 (1997). 9241125
13. K. Tanaka, K. Hayashi, T. Shingu, et al., Cardiovasc. Drugs Ther., 12, 19-28 (1998). 1:CAS:528:DyaK1cXjslGgu7o%3D
14. J. C. Tardif, G. Cote, J. Lesperanse, et al., Circulation, 97, 429-436 (1998). 9490236
15. H. Yokoi, H. Daida, Y. Kuwabara, et al., J. Am. Coll. Cardiol., 30, 855-862 (1997). 1:CAS:528:DyaK2sXms1Wgu74%3D